Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Susan Tofte

Nurse Practitioner, Family Portland, OR Nurse Practitioner

NPI 1316953870 CMS profile 1278056

3181 Sw Sam Jackson Park Rd, Portland, OR 97239

Open in the dashboard

General payments

$20,632

38 records reported · program years 2021–2024

Research payments

$4,796

Paid to them · 1 record reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Susan Tofte of Portland, OR is reported in the CMS Open Payments database as having received $20,632 across 38 general payments and $4,796 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $9,158 13
2023 General $6,417 14
2022 General $4,222 9
2022 Research $4,796 1
2021 General $835 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Tofte
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Susan Tofte were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Susan Tofte Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $835 $124 $35–$379 $132
2022 $4,222 $141 $44–$430 $149
2023 $6,417 $154 $49–$476 $160
2024 $9,158 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Genzyme Corporation $11,558 18 payments
  2. Arcutis Biotherapeutics, Inc. $7,543 13 payments
  3. Novartis Pharmaceuticals Corporation $1,125 2 payments
  4. Regeneron Healthcare Solutions, Inc. $207 3 payments
  5. Amgen Inc. $199 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Consulting Fee $16,962 8 payments
  2. Travel and Lodging $2,612 10 payments
  3. Food and Beverage $1,059 20 payments
Products named General payments · program years 2021–2024
  1. DUPIXENT Immunology $7,800 10 payments
  2. Zoryve $5,180 11 payments
  3. COSENTYX $1,125 2 payments
  4. DUPIXENT Inflammation And Immunology $207 3 payments
  5. Otezla $199 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2024
  1. Regeneron Pharmaceuticals, Inc. $4,796 1 payment

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record